Enjoy complimentary customisation on priority with our Enterprise License!
The global erectile dysfunction (ED) drugs market size is estimated to grow by USD 1.44 billion at a CAGR of 6.67% between 2023 and 2028.
The awareness of erectile dysfunction is growing across the world as it is an underdiagnosed and undertreated disorder. To overcome the lack of awareness regarding the conditions that lead to ED, several organizations, healthcare agencies, and government bodies are focusing on improving the quality of life of the patients. Furthermore, there are several erectile dysfunction support groups, under which patients are provided with information on personal experiences, the side effects of drugs, the dosage forms to be taken, information on the mechanism of action, and the half-life of the drugs used for the treatment of ED. Hence, the rising awareness of ED will fuel the growth of the market market during the forecast period.
Technavio has segmented the market into End-user, Product, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the hospital pharmacy segment will be significant during the forecast period. The hospital comprises pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies and used for the treatment of either outpatients or inpatients. The ED drugs are found in hospital pharmacies for ED treatments. Hospital pharmacies are the preferred end-user for ED drugs. They may provide advice on drug dosages, interactions, and potential side effects, as well as monitor patient adherence to medication regimens. This can help to enhance patient outcomes.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was valued at USD 1.54 billion in 2018. Moreover, hospital pharmacies also play a key role in clinical trials. Hospital pharmacies are often involved in the preparation and dispensing of medications used in these trials. By participating in clinical trials, hospital pharmacies contribute to the development of new drugs. All such factors make hospital pharmacy a critical channel that drives the segment growth; this, in turn, is expected to drive the growth of the erectile dysfunction (ED) Drugs market during the forecast period.
Oral drugs were the first to be developed for the treatment of ED. These drugs have been dominating the market for a long time due to the ease of administration or self-administration. Moreover, the OTC availability of these drugs is a major factor that contributes to their large market share. Furthermore, the patent expiration of these drugs is paving the way for genericization, which is responsible for the declining growth of this segment. The patents for drugs such as VIAGRA and CIALIS have already expired in major economies such as Europe and the US. Hence, such factors are expected to impede the growth of the oral drugs segment of the erectile dysfunction drugs market during the forecast period.
Topical drugs for the treatment of ED have demonstrated significant improvements in penile erection. The topical drugs for the treatment of ED are available in the form of gels and creams. Vitaros (alprostadil) is one of the topical cream formulations developed by Apricus Biosciences. This drug was withdrawn by the company because of the inconvenience of use and poor response. Similar drugs are available in different regions across the world. The year-over-year growth of this segment is expected to increase. Thus, such factors are expected to drive the growth of the tropical drugs segment of the erectile dysfunction drugs market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The ED drugs market in North America is led by the US. The growth of the market is driven by the increasing prevalence of chronic diseases. In addition, menopausal symptoms, such as vulvovaginal and clitoral atrophic change, vaginal thinning, and decreased elasticity, further result in dryness and the onset of dyspareunia.
Furthermore, key drugs for ED, including VIAGRA and CIALIS, have faced patent expiration in countries such as the US and Canada. In addition, the US is a developed country, and the economic status of the population is favorable. Thus, they opt for such expensive alternative modes of treatment. The genericization and the increased adoption of alternative treatments are leading to the decelerating growth of the erectile dysfunction drugs market in North America during the forecast period.
The outbreak of COVID-19 in 2020 had a negative impact on the ED drugs market in North America. However, in 2021, the initiation of large-scale vaccination drives?lifted the lockdown and travel restrictions, which led to the resumption of supply chain activities. Consequently, the demand for ED drugs rebounded with access to hospitals and clinics being restored. Moreover, the region is witnessing growing approval of new drugs that treat ED. Thus, owing to these factors, the regional erectile dysfunction drugs market is expected to witness significant growth during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Endo International Plc: The company offers erectile dysfunction drug namely edex.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Rising demand for ED drugs is the key factor driving market growth. With the rising health consciousness across the world, there has been a significant increase in healthcare spending for sexual wellness. As a result of this, there has been a surge in the demand for drugs for the treatment of disorders such as ED. This demand is arising not only due to the OTC availability of drugs but also because of the increase in the number of prescriptions for ED. Owing to the availability of treatment guidelines, physicians are using drug therapies for the treatment of ED.
Furthermore, the therapeutic benefits of drugs, such as a longer half-life in the body and the ease of administration even via the sublingual route, are expected to drive the adoption of ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are also expected to drive the growth of the global erectile dysfunction (ED) market during the forecast period.
The presence of novel drug formulations in late stages of development is the primary trend shaping market growth. The market is dominated by the oral formulations of the drugs used for the treatment of ED. However, in the next five years, several novel formulations of ED drugs, such as topical gels, injectables, and suppositories, are expected to emerge in the market. These novel formulations will attract a large number of patients owing to their therapeutic benefits. They are also expected to widen the scope of treatment for ED.
Moreover, for instance, the MonoSol Rx tadalafil oral soluble film by Adamis Pharmaceuticals is currently in the pre-registration stage of evaluation for the treatment of ED. The drug is the first sublingual formulation and is the first film alternative to the oral tablets available for the treatment of ED. Thus, such developments are expected to propel the growth of the global erectile dysfunction (ED) market in focus during the forecast period.
Availability of generics is a challenge that affects market growth. The entry of generic drugs has resulted in hampering the revenue growth of the global ED drugs market. For example, the generic version of VIAGRA, such as sildenafil citrate, is approved by the FDA. Other generic drugs for erectile dysfunction include Avanafil, Tadalafil, and Vardenafil, which is also commercially available. The sales of Viagra have declined in recent years.
Moreover, the decline in sales of Viagra led to a decline in the market share of Pfizer, which impacted the revenue generation for the company. Also, the low cost of generics is the second major cause of the decline of the market. Generic versions of Ed drugs can be obtained at a minimal price. Hence, the availability of generics in the market will act as a challenge to the growth of the global erectile dysfunction (ED) market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Erectile Dysfunction (ED) Drugs Market Customer Landscape
The erectile dysfunction (ED) drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
|
Erectile Dysfunction (ED) Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
163 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.67% |
|
Market Growth 2024-2028 |
USD 1.44 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.22 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Bayer AG, Cadila Pharmaceuticals Ltd., Cipla Ltd., Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Futura Medical plc, Innovcare Lifesciences Pvt. Ltd., Lupin Ltd., Pfizer Inc., SK Inc., Teva Pharmaceutical Industries Ltd., TTK Healthcare Ltd., Viatris Inc., and VIVUS LLC |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download the Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
